SANUWAVE Health Inc

SANUWAVE Health Inc(SNWV)の株式分析

$2.210

-0.040 (-1.79%)終値時点

Loading chart…
高値
2.650
始値
2.340
出来高加重平均価格
2.32
出来高
361.26K
時価総額
—
安値
2.105
売買代金
838.71K
EV/EBITDA(TTM)
-141.67

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others.

sanuwave.com

AI分析 of SANUWAVE Health Inc (SNWV)

売り

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

バリュエーション指標

SANUWAVE Health Inc(SNWV)の現在の予想PERは18.25で、5年平均は21.60です。

予想PER

適正
5年平均 P/E
21.60
現在のP/E
18.25
割高
37.29
割安
5.92

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
-5.23
現在のEV/EBITDA
-141.67
割高
58.87
割安
-69.32

予想PSR

割安
5年平均 P/S
2.63
現在のP/S
0.30
割高
4.90
割安
0.35

Alphio AI による SNWV の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%SNWV

$40.32

シナリオ価格

基

基本

基本 · 50%SNWV

$36.11

シナリオ価格

弱

弱気

弱気 · 25%SNWV

$28.03

シナリオ価格

イベントタイムライン

2026-11-05 (ET)

10:01:00

SANUWAVE Health Inc Trading Resumes

10:00:00

SANUWAVE Health Inc Trading Halted Due to Volatility

2026-07-13 (ET)

17:00:00

Sanuwave Health Q2 Revenue Expected to Reach $9.6M-$9.8M

2026-05-12 (ET)

17:10:00

Sanuwave Reports Q1 Revenue of $9.6M

17:10:00

Sanuwave Health Maintains FY26 Revenue View of $51M-$55M

ニュース

SNWV のよくある質問 — Alphio AI が回答

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others. It operates in the Healthcare sector.

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める